I
104TH CONGRESS
2D SESSION
H. R. 3293
To amend title XIV of the Public Health Service Act (commonly known
as the Safe Drinking Water Act) to establish a screening program for
estrogenic substances.
IN THE HOUSE OF REPRESENTATIVES
APRIL 23, 1996
Mrs. LOWEY introduced the following bill; which was referred to the
Committee on Commerce
A BILL
To amend title XIV of the Public Health Service Act (com-
monly known as the Safe Drinking Water Act) to estab-
lish a screening program for estrogenic substances.
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ‘‘Safe Drinking Water
Estrogenic Substances Screening Program Act’’.
SEC. 2. SAFE DRINKING WATER ACT; ESTABLISHMENT OF
SCREENING 
PROGRAM 
FOR 
ESTROGENIC
SUBSTANCES.
Title XIV of the Public Health Service Act (com-
monly known as the Safe Drinking Water Act) (42 U.S.C.
300f et seq.), as amended by Public Law 104–66, is
amended in section 1442 by adding at the end the follow-
ing subsection:
‘‘(f) SCREENING PROGRAM.—
‘‘(1) DEVELOPMENT.—Not later than 1 year
after the date of enactment of this subsection, the
Administrator shall develop a screening program,
using appropriate validated test systems, to deter-
mine whether certain substances may have an effect
in humans that is similar to an effect produced by
a naturally occurring estrogen, or such other endo-
crine effect as the Administrator may designate.
‘‘(2) IMPLEMENTATION.—Not later than 2
years after the date of enactment of this subsection,
after obtaining review of the screening program de-
scribed in paragraph (1) by the scientific advisory
panel established under section 25(d) of the Act of
June 25, 1947 (chapter 125), and the Science Advi-
sory Board established by section 8 of the Environ-
mental Research, Development, and Demonstration
in paragraph (1), and submit information ob-
tained from the testing to the Administrator,
within a time period that the Administrator de-
termines is sufficient for the generation of the
information.
‘‘(B) FAILURE
TO
SUBMIT
INFORMA-
TION.—
‘‘(i) SUSPENSION.—If a person re-
ferred to in subparagraph (A) fails to sub-
mit the information required under such
subparagraph within the time period estab-
lished by the order, the Administrator shall
issue a notice of intent to suspend the sale
or distribution of the substance by the per-
son. Any suspension proposed under this
subparagraph shall become final at the end
of the 30-day period beginning on the date
that the person receives the notice of in-
tent to suspend, unless during that period
a person adversely affected by the notice
requests a hearing or the Administrator
determines that the person referred to in
subparagraph (A) has complied fully with
this paragraph.
‘‘(ii) HEARING.—If a person requests
a hearing under clause (i), the hearing
shall be conducted in accordance with sec-
tion 554 of title 5, United States Code.
The only matter for resolution at the hear-
ing shall be whether the person has failed
to submit information required under this
paragraph. A decision by the Adminis-
trator after completion of a hearing shall
be considered to be a final agency action.
‘‘(iii) 
TERMINATION
OF
SUSPEN-
SIONS.—The Administrator shall terminate
a suspension under this subparagraph is-
sued with respect to a person if the Ad-
ministrator determines that the person has
complied fully with this paragraph.
‘‘(6) AGENCY ACTION.—In the case of any sub-
stance that is found to have a potential adverse ef-
fect on humans as a result of testing and evaluation
under this subsection, the Administrator shall take
such action, including appropriate regulatory action
by rule or by order under statutory authority avail-
able to the Administrator, as is necessary to ensure
the protection of public health.
‘‘(7) REPORT TO CONGRESS.—Not later than 4
years after the date of enactment of this subsection,
the Administrator shall prepare and submit to Con-
gress a report containing—
‘‘(A) the findings of the Administrator re-
sulting from the screening program described in
paragraph (1);
‘‘(B) recommendations for further testing
and research needed to evaluate the impact on
human health of the substances tested under
the screening program; and
‘‘(C) recommendations for any further ac-
tions (including any action described in para-
graph (6)) that the Administrator determines
are appropriate based on the findings.’’.
Æ